Research

A national trial (Pfizer) focused on pediatric patients who have been diagnosed with Alopecia Areata.

Who qualifies?

· Age of participants 6 to <12 years old

· Diagnosed with Alopecia Areata with at least 50% scalp hair loss, without evidence of terminal hair regrowth within the previous 12 months.

· Documented evidence of having received varicella vaccination (2 doses) OR evidence of prior exposure to varicella.

A national trial (Sanofi Corp.) focused on patients who have been diagnosed with Atopic Dermatitis.

Who qualifies?

· Age of participants 12 years or older

· Documented history of inadequate response to a biologic AD medication or oral JAK therapy

a. >4 months or longer for biologic

b. >2 months or longer for JAK

· Any other prominent skin conditions besides AD.

A national trial (Incyte Corp.) focused on pediatric patients who have been diagnosed with Hidradenitis Suppurativa.

Who qualifies?

· Age of participants >=12 to <18 years

· Diagnosis of moderate to severe Hidradenitis Suppurativa for at least 3 months.

· Inadequate response to at least a 3-month course of at least one conventional systemic therapy (oral antibiotic or biologic drug) for Hidradenitis Suppurativa.

A national trial (Incyte Corp.) focused on pediatric patients who have been diagnosed with Hidradenitis Suppurativa.

Who qualifies?

· Age of participants 12 or older

· Diagnosis of HS for at least 6 months based on clinical history & physical examination, as performed by a dermatologist.

· Mild to moderate HS with at least 2 distinct anatomical areas.

· Failure to any of the following:

-Topical or systemic antibiotics

-Topical antiseptics or systemic antibiotics

-JAK or Biologic inhibitors

A national trial (Incyte Corp.) focused on patients who have been diagnosed with Prurigo Nodularis.

Who qualifies?

· Age range of participants 18 to 75 years

· Diagnosis of PN for at least 3 months.

· Rating your itch a 7 or higher on a scale 1-10.

· 20 or more lesions on 2 different body regions.

· History of treatment failure, demonstrated intolerance, or contraindication to previous PN treatments.

· Taken any of these medications in the past or currently on:

-Topical or systemic antibioticsa

-Topical antiseptics or systemic antibiotics

-JAK or Biologic inhibitors

Who qualifies?

• ≥18 years of age or older at time of Screening Visit.
• Histologically confirmed invasive Cutaneous Squamous Cell Carcinoma.
• CSCC lesion must be located on either the Head/Neck area, hand, or pre-tibial surface.
• Patients will be randomized to either MOHS surgery (standard of care) or cemipilimab injections for treatment of CSCC lesion. 

A national trial (Incyte Corp.) focused on pediatric patients who have been diagnosed with Vitiligo.

Who qualifies?

· Age of participants 2 to <12 years of age

· Diagnosis of PN for at least 3 months.

· Diagnosis is nonsegmental vitiligo with depigmented area including on the face and non-facial areas.

· Pigmented hair within some of the areas of vitiligo on the face.

Allegro global Phase 2b/3 study for evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have 50% or greater scalp hair loss. The study is placebo-controlled, meaning that some patients entering the study will not receive active study drug but will receive tablets with no active ingredients (a placebo). This is a dose-ranging study, investigating 5 different dosing regimens. It will be double-blinded, meaning that the sponsor, the study doctors, the staff, and the patients will not know whether a patient is on active study drug (or the dose) or placebo.

https://clinicaltrials.gov/ct2/show/NCT03732807

• Alopecia areata is an autoimmune disorder that causes loss of hair.
• We are studying the use of ritlecitinib in this condition.
• Status: closed to enrollment

B7981031 Study to evaluate the pharmacokinetics (how the medicine is changed and eliminated from your body after you take it) and pharmacodynamics (effects of the medicine in the body) of the study medicine (called Ritlecitinib) in children of 6 to <12 years of age with Alopecia Areata, a condition of scalp hair loss. 12 children with alopecia areata will be participating in this study. All participants will receive study medicine with a dose of 20 milligram (mg) orally once daily for 7 days. 5 blood samples will be collected on day 7 for pharmacokinetic evaluation and 2 blood samples each at screening and on Day 7 will be collected for pharmacodynamic evaluation. Participants will take part in the study for about 10 weeks.

https://clinicaltrials.gov/study/NCT05650333

• Alopecia areata is an autoimmune disorder that causes loss of hair.
• We are studying the use of ritlecitinib in this condition.
• We are looking for children 6 to < 12 years of age.
• Status: Closed

ARQ 151-315 Study for assessing the safety and efficacy of ARQ-151 cream vs vehicle applied once a day for 4 weeks by subjects with atopic dermatitis (eczema).

https://clinicaltrials.gov/ct2/show/NCT04845620

• Atopic dermatitis is a condition that causes chronic itchy red skin. It is sometimes associated with allergies or asthma.
• We are looking for children ages 2-5 with moderate atopic dermatitis of the skin to enroll in a study that uses a non-steroid based topical treatment.
• Status: closed

230LE301 (AMETHYST) is a study to assess the efficacy and safety of BIIB059 (Litifilimab) in participants with active subacute cutaneous lupus erythematosus (SCLE) and/​or chronic cutaneous lupus erythematosus (CCLE) with or without systemic manifestations and refractory and/​or intolerant to antimalarial therapy. 

https://clinicaltrials.gov/study/NCT05531565 

• Cutaneous Lupus is an autoimmune disease that causes the body to attack healthy skin. 
• We are studying the use of litifilimab in this condition 
• We are looking for only adult participants 18 and older. 
• Status: Enrolling soon. 

BE HEARD Study for evaluation of efficacy and safety of bimekizumab for the treatment of moderate to severe hidradenitis suppurativa.

https://clinicaltrials.gov/ct2/show/NCT04242498

• Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition that affects up to 4% of the world’s population.
• HS causes painful nodules, abscesses, draining sinuses and scarring to form in body folds, including axillae, inframammary areas, groin, buttocks and others.
• Bimekizumab is an IL-17A and IL-17F inhibitor that is injected subcutaneously.
• Just under 1000 participants at approximately 220 studies centers across North America, Europe and Asia Pacific.
• Status: Open

Lichen Planus Study for evaluation of the safety and efficacy of ixekizumab in lichen planus and lichen planopilaris clinical response by Total Body Surface (TBS) determination, Investigator Global Assessment (IGA) Score, Lichen Planopilaris Activity Index (LPPAI), and Frontal Fibrosing Alopecia Severity Score (FFASS).

https://clinicaltrials.gov/ct2/show/NCT05030415

• Lichen planus and lichen planopilaris is a condition that causes itchy lesions on the skin or hairloss with itching and inflammation
• We are studying the use of an injectable medication ixekizumab in patients with this diagnosis
• Status: Currently enrolling

B7981040 (Tranquillo) is a Phase 3 randomized, double-blind, 52-week placebo-controlled, multi-center study investigating the efficacy, safety, and tolerability of ritlecitinib in adult and adolescent participants with non-segmental vitiligo (both active and stable vitiligo). 

https://clinicaltrials.gov/study/NCT05583526 

• Vitiligo is an autoimmune disease that causes loss of pigment in skin. 
• We are studying the use of ritlecitinib in this condition 
• We are looking for adolescent and adult participants 12 and older. 
• Status: Currently enrolling 

PEGASUS Study for evaluation of efficacy and safety of oral PRN1008 in moderate to severe pemphigus.

https://clinicaltrials.gov/ct2/show/NCT03762265

• Pemphigus vulgaris (PV) is a chronic autoimmune blistering disorder seen in up to 2.7/100,000 people worldwide, however PV is seen with higher frequency in New Mexico.
• PV can cause painful ulcerations on the skin and on the oral and genital mucosa.
• PRN1008 is a Bruton Tyrosine Kinase inhibitor that is taken orally
• 120 participants are enrolled worldwide
• Status: Waiting list only

Celldex Study for exploring the safety, clinical effect, pharmacodynamics, and pharmacokinetics of CDX-0159 (barzolvolimab) in patients with Prurigo Nodularis.

https://clinicaltrials.gov/ct2/show/NCT04944862

• Prurigo Nodularis is a skin condition causing itchy areas that form bumps on the skin.
• We are studying the use of a new medication barzolvolimab to improve these skin lesions in adults.
• Status: Currently enrolling

LITE Study for comparing the effectiveness, safety (tolerability), and duration of treatment response at 12 weeks of home versus office-based narrowband ultraviolet B phototherapy for the treatment of psoriasis. Physician Global Assessment (PGA) and Dermatology Life Quality Index (DLQI) will be used to assess effectiveness, safety (tolerability), and duration of treatment response. This is a three year pragmatic, randomized, active comparator effectiveness study.

https://clinicaltrials.gov/ct2/show/NCT03726489 

• Psoriasis is a common chronic inflammatory skin condition
• Phototherapy or light therapy can be used to improve psoriasis and is typically done in an office setting
• We are studying the use of an at home phototherapy device. Participants will be randomized to using phototherapy in the office or at home.
• Status: closed